FDA approves new drug treatments for type 2 diabetes
On Jan. 25, 2013, the U.S. Food and Drug Administration (FDA) approved three new related products for the treatment of type 2 diabetes: Nesina…
Technology
A new surgical intervention for reflux treatment
Learn about LINX, a surgical procedure for treating chronic gastroesophageal reflux disease.
CDC publishes updates to immunization schedules for children and adults
Vaccines are known as one of the greatest achievements in public health over the last century. And each year, it seems more vaccines are…
FDA approves seasonal flu vaccine made using novel technology
On Jan. 16, 2012, the U.S. Food and Drug Administration (FDA) approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus)…
FDA approves Botox for treatment of overactive bladder
On Jan. 18, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who…
FDA issue draft guidance on making opioids harder to abuse
On Jan. 9, 2012, the U.S. Food and Drug Administration (FDA) issued a draft guidance document to assist industry in developing new formulations of…
FDA expands Zytiga’s use for late-stage breast cancer
On Dec. 10, the U.S. Food and Drug Administration expanded the approved use of Zytiga (abiraterone acetate) to treat men with metastatic castration-resistant prostate…
FDA permits marketing of device to seal lung punctures
On Dec. 19, the U.S. Food and Drug Administration allowed marketing of the Bio-Seal Lung Biopsy Tract Plug System, a device that seals punctures…
Inhaled therapies for cystic fibrosis: Current and future trends
Several therapies are available to help patients with this progressive disease who develop airway infections.
FDA approves first flu vaccine using new manufacturing technique
On Nov. 20, the U.S. Food and Drug Administration (FDA) approved Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using…
FDA approves Xeljanz for rheumatoid arthritis
On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis who…
FDA approves new drug treatments for type 2 diabetes
On Jan. 25, 2013, the U.S. Food and Drug Administration (FDA) approved three new related products for the treatment of type 2…
A new surgical intervention for reflux treatment
Learn about LINX, a surgical procedure for treating chronic gastroesophageal reflux disease.
CDC publishes updates to immunization schedules for children and adults
Vaccines are known as one of the greatest achievements in public health over the last century. And each year, it seems more…
FDA approves seasonal flu vaccine made using novel technology
On Jan. 16, 2012, the U.S. Food and Drug Administration (FDA) approved Flublok, the first trivalent influenza vaccine made using an insect…
FDA approves Botox for treatment of overactive bladder
On Jan. 18, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Botox (onabotulinumtoxinA) to treat adults with overactive…
FDA issue draft guidance on making opioids harder to abuse
On Jan. 9, 2012, the U.S. Food and Drug Administration (FDA) issued a draft guidance document to assist industry in developing new…
FDA expands Zytiga’s use for late-stage breast cancer
On Dec. 10, the U.S. Food and Drug Administration expanded the approved use of Zytiga (abiraterone acetate) to treat men with metastatic…
FDA permits marketing of device to seal lung punctures
On Dec. 19, the U.S. Food and Drug Administration allowed marketing of the Bio-Seal Lung Biopsy Tract Plug System, a device that…
Inhaled therapies for cystic fibrosis: Current and future trends
Several therapies are available to help patients with this progressive disease who develop airway infections.
FDA approves first flu vaccine using new manufacturing technique
On Nov. 20, the U.S. Food and Drug Administration (FDA) approved Flucelvax, the first seasonal influenza vaccine licensed in the United States…
FDA approves Xeljanz for rheumatoid arthritis
On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid…
Test Your Knowledge
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.